MedPath

Cullinan Therapeutics

🇺🇸United States
Ownership
-
Employees
85
Market Cap
$1B
Website
Introduction

Cullinan Management, Inc. is a biopharmaceutical company engages in developing oncology and immuno-oncology therapies. The company was founded by Patrick R. Baeuerle on 15 September, 2016 and is headquartered in Cambridge, MA.

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus

Phase 1
Recruiting
Conditions
SLE
SLE (Systemic Lupus)
Interventions
First Posted Date
2024-09-25
Last Posted Date
2025-05-06
Lead Sponsor
Cullinan Therapeutics Inc.
Target Recruit Count
24
Registration Number
NCT06613360
Locations
🇦🇺

Cullinan Investigative Site, Victoria Park, Australia

🇲🇩

Arensia Research Clinic, Chisinau, Moldova, Republic of

A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma

Phase 1
Recruiting
Conditions
Multiple Myeloma
Interventions
First Posted Date
2024-04-24
Last Posted Date
2025-02-03
Lead Sponsor
Cullinan Therapeutics Inc.
Target Recruit Count
30
Registration Number
NCT06381141
Locations
🇺🇸

Mt. Sinai, New York, New York, United States

🇺🇸

Memorial Sloan Kettering (MSK), New York, New York, United States

🇺🇸

University of Texas Southwestern Medical Center, Dallas, Texas, United States

CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Advanced Solid Tumor
Interventions
First Posted Date
2023-09-13
Last Posted Date
2025-03-03
Lead Sponsor
Cullinan Therapeutics Inc.
Target Recruit Count
86
Registration Number
NCT06035744
Locations
🇺🇸

USC Norris Comprehensive Cancer Center, Los Angeles, California, United States

🇺🇸

Orlando Health, Orlando, Florida, United States

🇺🇸

University of Chicago, Chicago, Illinois, United States

and more 2 locations

A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)

Phase 1
Active, not recruiting
Conditions
NHL
NHL, Relapsed, Adult
Interventions
First Posted Date
2023-05-30
Last Posted Date
2024-05-02
Lead Sponsor
Cullinan Therapeutics Inc.
Target Recruit Count
90
Registration Number
NCT05879744
Locations
🇺🇸

Winship Cancer Institute at Emory University, Atlanta, Georgia, United States

🇺🇸

University of Texas Southwestern Medical Center, Dallas, Texas, United States

🇺🇸

City of Hope, Duarte, California, United States

and more 3 locations

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Phase 1
Recruiting
Conditions
Relapsed/Refractory Acute Myeloid Leukemia (AML)
Myelodysplastic Syndrome (MDS)
Interventions
First Posted Date
2021-12-03
Last Posted Date
2023-12-27
Lead Sponsor
Cullinan Therapeutics Inc.
Target Recruit Count
60
Registration Number
NCT05143996
Locations
🇺🇸

New York University, New York, New York, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

UCLA, Los Angeles, California, United States

and more 4 locations

A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Advanced Solid Tumor
Interventions
First Posted Date
2021-11-11
Last Posted Date
2025-02-03
Lead Sponsor
Cullinan Therapeutics Inc.
Target Recruit Count
410
Registration Number
NCT05117476
Locations
🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

City of Hope, Irvine, California, United States

🇺🇸

Florida Cancer Specialists, Sarasota, Florida, United States

and more 19 locations

A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer

Phase 1
Active, not recruiting
Conditions
Non Small Cell Lung Cancer
EGFR Exon 20 Mutation
Interventions
First Posted Date
2019-07-30
Last Posted Date
2025-03-13
Lead Sponsor
Cullinan Therapeutics Inc.
Target Recruit Count
284
Registration Number
NCT04036682
Locations
🇰🇷

Asan Medical Center (AMC), Soeul, Korea, Republic of

🇺🇸

Pacific Cancer Medical Center, Inc, Anaheim, California, United States

🇺🇸

City of Hope Comprehensive Cancer Center, Duarte, California, United States

and more 61 locations

Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)

Phase 1
Terminated
Conditions
Nasopharyngeal Carcinoma
Nasopharyngeal Cancer
Interventions
First Posted Date
2018-09-24
Last Posted Date
2023-08-15
Lead Sponsor
Cullinan Therapeutics Inc.
Target Recruit Count
14
Registration Number
NCT03682055
Locations
🇺🇸

Stanford University, School of Medicine, Stanford Cancer Institute, Stanford, California, United States

🇸🇬

National Cancer Centre Singapore, Singapore, Singapore

🇺🇸

The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

and more 3 locations
© Copyright 2025. All Rights Reserved by MedPath